Catalyst OrthoScience introduces the Archer™ R1 Reverse Shoulder System: Rebrands its Archer™ CSR Total Shoulder System

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, is introducing its new Archer™ R1 Reverse Shoulder System as its Archer™ CSR Total Shoulder System continues to gain market share.

“Since we introduced our first product in 2016, Catalyst has remained targeted on the shoulder arthroplasty space,” said Brian K. Hutchison, chairman and CEO of Catalyst OrthoScience. “We are building out a comprehensive, novel portfolio focused precisely on that market. The tenets of our product portfolio are centered around precise, targeted placement of bone-sparing implants. Our next generation implant design, paired with unique, patented instrumentation and streamlined surgical techniques, allows for surgeon-targeted implant positioning. We feel the Archer product family name represents these tenets well in the market place.”

Recently, Catalyst OrthoScience announced 510(k) clearance of the Archer R1 Reverse Shoulder System, expanding its product portfolio with multiple arthroplasty options. Catalyst’s reverse shoulder system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants. Catalyst is starting a limited user release in the United States this quarter followed by a commercial launch later in 2021.

As part of this important milestone, the company is rebranding its flagship stemless, ellipsoid anatomic system to the Archer CSR Total Shoulder System. Since its introduction in 2016, Catalyst’s Archer CSR system has experienced explosive adoption and growth. The Archer CSR system is unique, offering precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. It is a single-tray, bone-preserving total shoulder arthroplasty system containing a precision elliptical humeral head and less invasive glenoid component, using patented instrumentation designed for consistent anatomic joint line restoration and glenoid insertion.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”